M B Lens1, J A Newton-Bishop. 1. Genetic Epidemiology Division, Cancer Research UK, St James's University Hospital, Leeds, UK. Markolens@aol.com
Abstract
BACKGROUND: Several epidemiological studies have suggested an association between cutaneous melanoma and non-Hodgkin's lymphoma. METHODS: We pooled the data from seven cohort studies and calculated the risk of secondary occurrence of cutaneous melanoma after non-Hodgkin's lymphoma, and of non-Hodgkin's lymphoma subsequent to the occurrence of cutaneous melanoma. RESULTS: There were 137 612 patients with primary non-Hodgkin's lymphoma and 109 532 patients with primary cutaneous melanoma. We found a statistically significant increased risk of non-Hodgkin's lymphoma among cutaneous melanoma survivors [standardised incidence ratio (SIR) 2.01, 95% confidence interval (CI) 1.79-2.24] and cutaneous melanoma among non-Hodgkin's lymphoma survivors (SIR 1.41, 95% CI 1.26-1.58). CONCLUSION: Our study confirmed an association between cutaneous melanoma and non-Hodgkin's lymphoma occurring in the same patient indicative of a need to examine further the role of the common risk factors.
BACKGROUND: Several epidemiological studies have suggested an association between cutaneous melanoma and non-Hodgkin's lymphoma. METHODS: We pooled the data from seven cohort studies and calculated the risk of secondary occurrence of cutaneous melanoma after non-Hodgkin's lymphoma, and of non-Hodgkin's lymphoma subsequent to the occurrence of cutaneous melanoma. RESULTS: There were 137 612 patients with primary non-Hodgkin's lymphoma and 109 532 patients with primary cutaneous melanoma. We found a statistically significant increased risk of non-Hodgkin's lymphoma among cutaneous melanoma survivors [standardised incidence ratio (SIR) 2.01, 95% confidence interval (CI) 1.79-2.24] and cutaneous melanoma among non-Hodgkin's lymphoma survivors (SIR 1.41, 95% CI 1.26-1.58). CONCLUSION: Our study confirmed an association between cutaneous melanoma and non-Hodgkin's lymphoma occurring in the same patient indicative of a need to examine further the role of the common risk factors.
Authors: Megan M Herr; Sara J Schonfeld; Graça M Dores; Diana R Withrow; Margaret A Tucker; Rochelle E Curtis; Lindsay M Morton Journal: J Natl Cancer Inst Date: 2018-11-01 Impact factor: 13.506
Authors: Unhee Lim; D Michal Freedman; Bruce W Hollis; Ronald L Horst; Mark P Purdue; Nilanjan Chatterjee; Stephanie J Weinstein; Lindsay M Morton; Arthur Schatzkin; Jarmo Virtamo; Martha S Linet; Patricia Hartge; Demetrius Albanes Journal: Int J Cancer Date: 2009-02-15 Impact factor: 7.396
Authors: I A Bilmon; L J Ashton; R E Le Marsney; A J Dodds; T A O'Brien; L Wilcox; I Nivison-Smith; B Daniels; C M Vajdic Journal: Bone Marrow Transplant Date: 2014-02-17 Impact factor: 5.483
Authors: Pablo Fernandez-Crehuet Serrano; Jose Luis Fernandez-Crehuet Serrano; Mohamed Farouk Allam; Rafael Fernandez-Crehuet Navajas Journal: Int J Prev Med Date: 2016-05-04